Strategies for treating HIV-related lipodystrophy

Expert Opinion on Investigational Drugs

Volumn 10, Issue 8, 2001, Pages 1443-1456

  Garcia Viejo M A ^a   Ruiz M ^a   Martinez E ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Adipose tissue; Antiretrovirals; HIV; Lipodystrophy; Metabolic abnormalities; Protease inhibitors

Indexed keywords

ABACAVIR; ANABOLIC AGENT; ANDROGEN; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; CYCLOSPORIN; DILTIAZEM; ERYTHROMYCIN; ESTROGEN; FENOFIBRATE; GEMFIBROZIL; GLUCOCORTICOID; ITRACONAZOLE; METFORMIN; MEVINOLIN; NEVIRAPINE; NICOTINIC ACID; PRAVASTATIN; PROTEINASE INHIBITOR; RECOMBINANT GROWTH HORMONE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SIMVASTATIN; STAVUDINE; THIAZIDE DIURETIC AGENT; THIAZOLE DERIVATIVE; THYROID HORMONE; UNINDEXED DRUG;

BODY FAT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC DISEASE; DATA ANALYSIS; DIET; DRUG USE; EXERCISE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; LIPOSUCTION; LIVER TOXICITY; METABOLIC DISORDER; MORBIDITY; MORTALITY; MUSCLE DISEASE; MYALGIA; MYOPATHY; PATHOGENESIS; POPULATION; PREVALENCE; QUALITY OF LIFE; REVIEW; RHABDOMYOLYSIS; SMOKING CESSATION; WASTING SYNDROME;

ANIMALS; ANTI-HIV AGENTS; ANTILIPEMIC AGENTS; BODY COMPOSITION; HIV INFECTIONS; HIV WASTING SYNDROME; HUMANS; LIPODYSTROPHY;

EID: 0034895353     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.8.1443     Document Type: Review

References (150)

1. From lipodystrophy syndromes to diabetes mellitus
2. Lipodystrophies
3. Metabolic abnormalities and body fat redistribution in HIV-1 infected patients: The lipodystrophy syndrome
4. Leptin levels in HIV-positive patients treated with HAART
5. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection
6. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy
7. Osteopenia in a randomized, multicenter study of protease inhibitor substitution in patients with the lipodystrophy syndrome and well-controlled HIV viremia
8. Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir
9. Increased abdominal visceral fat is associated with reduced bone density in HIV-infected men with lipodystrophy
10. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
11. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy
12. Indinavir-associated lipodystrophy
13. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
14. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects
15. For the Italian Registry of Antiretroviral Post-Exposure Prophylaxis: Effect of short-course of antiretroviral agents on serum triglycerides of healthy individuals
16. Protease inhibitor-associated hyperinsulinaemia
17. Metabolic effects of indinavir in healthy HIV-seronegative men
18. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
19. Metabolic abnormalities and use of HIV-1 protease inhibitors
20. HIV-protease inhibitors
21. Lipodystrophy in patients naive to HIV protease inhibitors
22. Lipodystrophy associated with nevirapine-containing antiretroviral therapies
23. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection
24. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection
25. Antiretroviral therapy and the lipodystrophy syndrome
26. The mechanism of insulin resistance caused by HIV protease inhibitor therapy
27. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance
28. The HIV protease inhibitor indinavir decreases insulin- and contraction-stimulated glucose transport in skeletal muscle
29. The HIV protease inhibitor nelfinavir induces insulin resistance and increases basal lipolysis in 3T3-L1 adipocytes
30. Effect of stavudine on mitochondrial genome and fatty acid oxidation in lean and obese mice
31. Mitochondrial toxicity hypothesis for lipoatrophy: A refutation
32. Studies of body composition and fat distribution in HIV-infected and control subjects
33. Adipose redistribution in human immunodeficiency virus-seropositive patients: Association with CD4 response
34. Fat redistribution in HIV-infected patients: A new hormonal-immune disorder?
35. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: A prospective cohort study
36. Metabolic disorders in a cohort of patients treated with highly aggressive antiretroviral therapies during primary HIV-1 infection
37. Incidence of lipodystrophy in patients with primary HIV-1 infection treated with HAART
38. Lipodystrophy following antiretroviral therapy of primary HIV infection
39. Incidence of clinical lipodystrophy in HIV-1-infected patients treated during primary infection
40. Dietary intake, serum lipids, insulin resistance and body composition in the era of highly active antiretroviral therapy: Diet FRS Study
41. Genetic and environmental influences on total-body and central abdominal fat: The effect of physical activity in female twins
42. Is there a relationship between hepatitis C virus infection and antiretroviral-associated lipoatrophy
43. Treatments for wasting in patients with the acquired immunodeficiency syndrome
44. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
45. Declining morbidity and mortality among patients with advanced HIV infection
46. For the Eurosida Study Group: Changing patterns of mortality across Europe in patients infected with HIV
47. Recovery of replication-competent HIV despite prolonged suppression of HIV viremia
48. Identification of a reservoir of human immunodeficiency virus-1 in patients on highly active antiretroviral therapy
49. The effect of protease inhibitors on weight and body composition in HIV-infected patients
50. Effect of indinavir on HIV-related wasting
51. Beneficial effects of protease inhibitors on body composition and energy expenditure: A comparison between HIV-infected and AIDS patients
52. Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy
53. Body weight changes with protease inhibitor treatment in undernourished HIV-infected patients
54. Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy
55. Elevated resting energy expenditure among seropositive persons receiving highly active antiretroviral therapy
56. Hypertriglyceridemia in the acquired immunodeficiency syndrome
57. Alteration of tumor necrosis factor-α T-cell homeostasis following potent antiretroviral therapy: Contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome
58. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy
59. Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immune deficiency syndrome
60. Reversal of cachexia in patients treated with potent antiretroviral therapy
61. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy
62. Insulin resistance and cardiovascular disease
63. Disorders of glucose metabolism in patients infected with human immunodeficiency virus
64. Incidence, characteristics, and prognosis of diabetes mellitus associated with protease inhibitors
65. Regional adiposity and morbidity
66. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II)
67. Plasma triglyceride level is a risk factor independent of HDL cholesterol level: A meta-analysis of population-based prospective studies
68. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors
69. Premature atherosclerosis in HIV-infected individuals: Focus on protease inhibitor therapy
70. Severe premature coronary artery disease with protease inhibitors
71. Vascular complications associated with the use of HIV protease inhibitors
72. Vascular complications associated with the use of HIV protease inhibitors
73. Increasing morbidity from myocardial infarction during HIV protease inhibitor treatment?
74. Sudden cardiac death in a patient on 2 years of highly active antiretroviral therapy: A case report
75. Myocardial infarction in HIV seropositive men in the era of HAART treatments in France
76. Changing spectrum of mortality due to human immunodeficiency virus: Analysis of 260 deaths during 1995-1999
77. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study
78. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database
79. Lipodystrophy syndrome in patients with HIV infection: Quality of life issues
80. Psychological impact of the lipodystrophy syndrome in HIV infection
81. The impact of experiencing lipodystrophy on the sexual behaviour and well-being among HIV-infected homosexual men
82. Detection and evaluation of dyslipoproteinemia
83. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus
84. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: Preliminary results of the LIPOCO study
85. Prevalence and predictive value of overweight in an urban HIV care clinic
86. Prevalence of lipodystrophy and metabolic abnormalities in the Multicenter AIDS Cohort Study (MACS)
87. Changes in body habirus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy: A 3.5 year study
88. Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy
89. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
90. Standards of medical care for patients with diabetes mellitus
91. Is there an optimal diet for the hypertriglyceridemic patient?
92. Preliminary guidelines for the evaluation and management of dyslipemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Disease Focus Group
93. Effects of dietary n-3 fatty acid supplementation in men with weight loss associated with the acquired immunodeficiency syndrome: Relation to indices of cytokine production
94. Adverse metabolic effect of omega-3 fatty acids in non-insulin-dependent diabetes mellitus
95. Long-term effects of fish oil on insulin resistance and plasma lipoprotein in NIDDM patients with hypertriglyceridemia
96. Soluble fiber and nondigestible carbohydrate effects on plasma lipids and cardiovascular risk
97. Nutrition recommendations and principles for people with diabetes mellitus
98. Diabetes mellitus and exercise
99. Screening and treating adults for lipid disorders (2)
100. Clinical, virological, and immunological benefit of switching the protease inhibitor by nevirapine in HAART experienced patients suffering lipodystrophy: 36-week follow-up
101. Risks and benefits of replacing protease inhibitors by nevirapine in patients under long-term successful triple combination therapy
102. A prospective open-label pilot trial of a maintenance nevirapine-containing regimen in patients with undetectable viral loads on protease inhibitor regimens for at least 6 months
103. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine
104. Protease inhibitor class-sparing maintenance therapy with abacavir + lamivudine + zidovudine in patients with long-term suppression of HIV-1 RNA
105. Improvement of lipodystrophy in HIV-1-infected subjects switching from 2 NRTI/PI to 2NRTI/abacavir (French substudy, CNA30017)
106. A novel use of abacavir to simplify therapy in PI-experienced patients succesfully treated with HAART
107. Partial improvement of lipodystrophy after switching from HIV-1 protease inhibitors to efavirenz
108. Evolution of lipodystrophy syndrome and lipidic profile in HIV patients after switching from protease inhibitors to efavirenz
109. Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy
110. Drug treatment of lipid disorders
111. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities
112. Atorvastatin for protease inhibitor-related hyperlipidaemia
113. Interactions among drugs for HIV and opportunistic infections
114. Drug interactions and the statins
115. Gemfibrozil effectively lowers protease inhibitor-associated hypertriglyceridemia in HIV-1-positive patients
116. A randomised, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridemia
117. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
118. Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy
119. Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial
120. Effects of troglitazone on insulin-sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus
121. Nutrition in the era of highly active antiretroviral therapy
122. A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution
123. Liposuction for protease-inhibitor-associated lipodystrophy
124. Suction-assisted lipectomy for lipodystrophy syndromes attributed to HIV-protease inhibitor use
125. Plastic surgery: Facial recontouring in lipodystrophic HIV-infected patients under HAART: Our experience
126. Surgical correction of facial lipoatrophy in patients under HAART
127. Effects of polylactic acid (New-Fill®) on bichat fat pads atrophia in HIV-infected patients under HAART
128. The effects of polylactic acid as therapy for lipoatrophy of the face
129. Lipodystrophy related to reverse transcriptase inhibitors in HAART: Effect of switching stavudine therapy
130. The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy
131. Improvement of facial lipoatrophy after substitution of stavudine
132. Replacement of stavudine by abacavir does not ameliorate lipoatrophy in HAART recipients
133. Complete reversibility of severe nucleoside-induced lipodystrophy
134. Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy
135. Switching from protease inhibitors to nevirapine has no effect on HAART-associated subcutaneous adipocyte apoptosis
136. A randomised trial of thymidine analogue withdrawal in lipoatrophic HIV patients, virologically controlled on protease sparing therapy: The PIILR extension study
137. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes
138. Insulin sensitiser drugs
139. Nonhypoglycemic effects of thiazolidinediones
140. Use of growth hormone and other anabolic agents in AIDS wasting
141. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy
142. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV
143. Recombinant human growth hormone improves truncal adiposity and "buffalo humps" in HIV-positive patients on HAART
144. Reversal of protease inhibitor-related visceral abdominal fat accumulation with recombinant human growth hormone
145. Fat redistribution syndrome and therapy with growth hormone
146. Effects of low dose recombinant growth hormone on BIA parameters and blood lipids in HIV-infected patients with lipodystrophy
147. Diabetes mellitus associated with recombinant human growth hormone for HIV wasting syndrome
148. Nandrolone decanoate: Use in HIV-associated lipodystrophy syndrome: A pilot study
149. Cushing's syndrome induced by megestrol acetate in a patient with AIDS